Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study (Investigational New Drugs, (2022), 40, 2, (290-299), 10.1007/s10637-021-01188-1)

Kyaw Z. Thein, Daniel D. Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic, Jatin Shah, Denái R. Milton, David S. Hong, Filip Janku, Lacey McQuinn, Bettzy A. Stephen, Rivka Colen, Brett W. Carter, Timothy A. Yap, Sarina A. Piha-Paul, Siqing Fu, Funda Meric-Bernstam, Aung Naing

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study was originally published electronically on the publisher’s internet portal on 25 September 2021 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to

Original languageEnglish (US)
Pages (from-to)463
Number of pages1
JournalInvestigational New Drugs
Volume40
Issue number2
DOIs
StatePublished - Apr 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study (Investigational New Drugs, (2022), 40, 2, (290-299), 10.1007/s10637-021-01188-1)'. Together they form a unique fingerprint.

Cite this